Torrence R J, Kavoussi L R, Catalona W J, Ratliff T L
Washington University School of Medicine, St. Louis, Missouri.
J Urol. 1988 May;139(5):941-4. doi: 10.1016/s0022-5347(17)42723-6.
Several factors were evaluated for prognostic significance in 104 patients with a history of recurrent superficial bladder cancer treated with a 6-week course of intravesical bacillus Calmette-Guerin. Purified protein derivative skin test reactivity, tumor stage, tumor grade and number of previous tumor recurrences were evaluated in all patients. In addition, the prognostic value of a granulomatous response in the bladder was evaluated in 62 of the 104 patients. A significant correlation was reconfirmed between purified protein derivative reactivity and status free of tumor (p equals 0.041) after additional followup on 62 patients from a previous report. A significant correlation also was observed in the total patient population (p equals 0.054). Over-all, 60 per cent of the 62 patients and 52 per cent of the 104 patients whose purified protein derivative test converted from negative to positive remained free of tumor, compared to only 28 per cent of the 62 patients and 28 per cent of the 104 whose test failed to convert to positive. Mean followup was 29.3 +/- 5.7 months in the 62 patient subgroup and 23.5 +/- 5.8 months in the total 104 patients. Bladder granuloma data were available only for the 62 patient subgroup in the previous report. With extended followup, the significant correlation previously reported between status free of tumor and granulomatous response on bladder biopsy was lost. Over-all, 29 of 37 patients (51 per cent) with granulomas compared to 8 of 25 (32 per cent) without granulomas remained free of tumor (p equals 0.132). Tumor stage and grade, and number of previous tumor recurrences failed to show a significant correlation to status free of tumor. These results show that with extended followup, granulomatous response in the bladder lost its statistical correlation with status free of tumor, while a significant correlation was maintained for purified protein derivative responsiveness. This level of statistical significance was borderline and the purified protein derivative skin test response should not be considered useful as a prognostic indicator in individual patients.
对104例复发性浅表性膀胱癌患者进行了卡介苗膀胱内灌注6周疗程治疗,评估了几个因素的预后意义。对所有患者评估了纯化蛋白衍生物皮肤试验反应性、肿瘤分期、肿瘤分级和既往肿瘤复发次数。此外,在104例患者中的62例中评估了膀胱肉芽肿反应的预后价值。对先前报告中的62例患者进行额外随访后,再次证实纯化蛋白衍生物反应性与无瘤状态之间存在显著相关性(p = 0.041)。在全部患者群体中也观察到显著相关性(p = 0.054)。总体而言,纯化蛋白衍生物试验从阴性转为阳性的62例患者中有60%、104例患者中有52%保持无瘤状态,相比之下,试验未转为阳性的62例患者中只有28%、104例患者中只有28%保持无瘤状态。62例患者亚组的平均随访时间为29.3±5.7个月,104例患者总体的平均随访时间为23.5±5.8个月。膀胱肉芽肿数据仅来自先前报告中的62例患者亚组。随着随访时间延长,先前报告的膀胱活检无瘤状态与肉芽肿反应之间的显著相关性消失。总体而言,有肉芽肿的37例患者中有29例(51%)保持无瘤状态,相比之下,无肉芽肿的25例患者中有8例(32%)保持无瘤状态(p = 0.132)。肿瘤分期、分级和既往肿瘤复发次数与无瘤状态未显示出显著相关性。这些结果表明,随着随访时间延长,膀胱肉芽肿反应与无瘤状态失去了统计学相关性,而纯化蛋白衍生物反应性则保持显著相关性。这种统计学显著性水平处于临界值,纯化蛋白衍生物皮肤试验反应不应被视为个体患者有用的预后指标。